Spinal cord injury (SCI) disrupts the blood–spinal cord barrier (BSCB) exacerbating damage by allowing harmful substances and immune cells to infiltrate spinal neural tissues from the vasculature. This leads to inflammation, oxidative stress, and impaired axonal regeneration. The BSCB, essential for maintaining spinal cord homeostasis, is structurally similar to the blood–brain barrier. Its restoration is a key therapeutic target for improving outcomes in SCI. Mesenchymal stromal/stem cells (MSCs) and their secreted extracellular vesicles (MSC-EVs) have gained attention for their regenerative, immunomodulatory, and anti-inflammatory properties in promoting BSCB repair. MSCs enhance BSCB integrity by improving endothelial–pericyte association, restoring tight junction proteins, and reducing inflammation. MSC-EVs, which deliver bioactive molecules, replicate many of MSCs’ therapeutic effects, and offer a promising cell-free alternative. Preclinical studies have shown that both MSCs and MSC-EVs can reduce BSCB permeability, promote vascular stability, and support functional recovery. While MSC therapy is advancing in clinical trials, MSC-EV therapies require further optimization in terms of production, dosing, and delivery protocols. Despite these challenges, both therapeutic approaches represent significant potential for treating SCI by targeting BSCB repair and improving patient outcomes.
Approximately 900,000 individuals worldwide experience a traumatic spinal cord injury (SCI) each year, with roughly 15.4 million people estimated by the World Health Organization to be living with SCI. The effects of SCI on the lives of affected individuals and their families can be profound. In addition to partial or complete loss of sensory and/or motor function below the level of the lesion, a high proportion of patients with spinal cord injuries experience: neuropathic pain, spasticity, bladder and bowel dysfunction, autonomic dysreflexia, adrenal insufficiency, infertility, or sexual dysfunction due to their injury. The disabilities associated with SCI result from both direct physical injury to neurons and glia and from secondary damage caused by a complex cascade of biochemical processes involving multiple cell types. These processes present many potential targets for intervening in outcomes and reducing disability. This review will summarize the complex pathophysiology of traumatic spinal cord lesions and describe the main strategies and agents being investigated for reducing disability and enhancing recovery after spinal cord injury and the note status of related clinical trials. The goal is to provide a framework for moving forward to develop better treatments for this life-changing condition.